samedan logo
 
 
spacer
home > pmps > winter 2021 > safe, flexible, and efficient containment
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Safe, Flexible, and Efficient Containment

The demand for, and development of, new oral solid dosage forms for oncology and hormone therapy is increasing – and so is the demand for containment solutions. When processing these highly potent substances, the protection of machine operators is paramount. At the same time, the quality of the final product is crucial since patients' health depends on it.

But how much containment is really necessary, and how can it be implemented economically and flexibly in the cost-intensive pharmaceutical industry? Ultimately, only a combination of modern and highly efficient systems with automated cleaning, proven processes, and years of expertise form the basis for successful containment.

NOEL, OEL, and OEB

The occupational exposure limit (OEL) for active substances can be determined in micrograms per cubic metre (μg/m3) by means of no observed effect level (NOEL) and the required safety factors. The OEL is the time-weighted average concentration of a substance in the air at the workplace, at which no acute or chronic damage to the health of employees is to be expected. The regulation is based on eight-hour exposure five days a week during working life.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Fritz-Martin Scholz is Product Manager for the product brand Hüttlin at Syntegon Technology. The Hüttlin portfolio includes high-shear mixer granulator systems and fluid bed systems from laboratory to production scale. Fritz-Martin holds a Master’s in Engineering and has many years of experience in R&D, product development, and product management in different industries, such as packaging technology and medical technology.
spacer
Fritz-Martin Scholz
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Clinerion’s revolutionary ANID technology for de-identification and identification of patient record data in Patient Network Explorer is now patent protected

New Clinerion patent constitutes a new technology for patient search and identification based on the electronic medical records of patients held by hospitals. The ANID technology involves exclusively the use of de-identified data, unlinked from identifiers, ensuring the privacy and security of patient information.
More info >>

White Papers

Mauritius Island – An Emerging Centre for R&D in Biotechnology and the Life Sciences

CIDP (Centre International de Développement Pharmaceutique)

Mauritius, the tropical island situated in the Indian Ocean and known worldwide for its beautiful beaches, is also internationally recognised for its rule of law, and political and social stability. Over the past few years, the economy has been successfully transitioned from a monocrop to a diversified innovation-driven and knowledge-based economy, resting on agribusiness, export-oriented manufacturing, tourism, financial services, property development and real estate, ICT-BPO, the seafood industry, a free port, logistics and a nascent ocean economy. Emerging sectors such as healthcare and life sciences are presenting some niche areas for the taking, and the enabling environment is being put in place to make it happen - especially in the light of sustained growth within pharmaceutical, medical device, and clinical research. Important international players are already in operation locally as the country has established the appropriate legal and regulatory frameworks based on international norms, for the development of a strong biomedical research sector.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement